Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 221-230 of 421 for breast cancer

Edit search filters
  1. A Study of AFP464 for Treating Patients with Solid Tumors that are Metastatic or Resistant to Treatment, and Cannot Be Removed By Surgery

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Individualizing Approaches To Surveillance Mammography In Older Breast Cancer Survivors - The I-MAMMO Study

    Rochester, MN

  3. A Study Of Pembrolizumab Alone As Therapy For Metastatic Triple-Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Phase 1 Study Of CLR 125 In Triple Negative Breast Cancer

    Jacksonville, FL, Rochester, MN

  5. Docetaxel And Cyclophosphamide Compared To Anthracycline-Based Chemotherapy In Treating Women With HER2-Negative Breast Cancer

    Rochester, MN

  6. Anastrozole And Letrozole After Surgery For The Treatment Of Stage I-III Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study Of Abemaciclib (LY2835219) In Women With HR+, HER2+ Locally Advanced Or Metastatic Breast Cancer

    Rochester, MN

  8. Taselisib And Enzalutamide In Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

    Rochester, MN

  9. A Study Of Niraparib Combined With Pembrolizumab (MK-3475) In Patients Who Have Triple-Negative Breast Cancer Or Ovarian Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Neratinib +/- Fulvestrant In Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

    Rochester, MN

.

Mayo Clinic Footer